Cargando…
A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer
Hepatocellular carcinoma (HCC) is the third most deadly cancer in the world. New treatment strategies are desperately needed due to limited standard therapies. Activation of the Erk, Akt, and STAT3pathways is implicated in the prognosis of HCC. The Se,Se′-1,4-phenylenebis(1,2-ethanediyl) bisisoselen...
Autores principales: | Tagaram, Hephzibah Rani S., Desai, Dhimant, Li, Guangfu, Liu, Dai, Rountree, C. Bart, Gowda, Kavitha, Berg, Arthur, Amin, Shantu, Staveley-O’Carroll, Kevin F., Kimchi, Eric T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932536/ https://www.ncbi.nlm.nih.gov/pubmed/27023566 http://dx.doi.org/10.3390/ph9020018 |
Ejemplares similares
-
Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma
por: Liu, Dai, et al.
Publicado: (2015) -
Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer
por: Liu, Dai, et al.
Publicado: (2018) -
Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity
por: Yang, Ming, et al.
Publicado: (2021) -
The Important Roles of Natural Killer Cells in Liver Fibrosis
por: Yang, Ming, et al.
Publicado: (2023) -
Diet and Gut Microbiota Interaction-Derived Metabolites and Intrahepatic Immune Response in NAFLD Development and Treatment
por: Yang, Ming, et al.
Publicado: (2021)